Novo Nordisk's Ozempic recommended for use in the EU for the treatment of arterial disease
Novo Nordisk (NVO.US) announced on Monday that the European Commission has recommended the use of its type 2 diabetes and obesity drug Ozempic for the treatment of peripheral artery disease (PAD) and its primary therapeutic issues.
The company stated that it expects the European Commission to update the drug's label in about two months
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments